HETEROCYCLIC INHIBITORS OF TYROSINE KINASE - University of Texas Patent Application

The European Patent Office published a new patent application (EP3962908A1) for heterocyclic compounds as tyrosine kinase inhibitors. The University of Texas System is the applicant, with inventors including Heymach, Robichaux, Nilsson, Jones, Cross, and Theroff. The patent application covers pharmaceutical compositions and methods of treatment, particularly for cancer (A61P 35/00).

For pharmaceutical and biotechnology companies developing tyrosine kinase inhibitors or related oncology therapies, this published patent establishes priority rights in European designated states. Competitors should conduct freedom-to-operate analyses and consider licensing arrangements. Research institutions and drug developers should monitor the patent prosecution progress, as the scope of granted claims may differ from the published application.